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AbstrAct
CCDC6 gene product is a pro-apoptotic protein substrate of ATM, whose loss 
or inactivation enhances tumour progression. In primary tumours, the impaired 
function of CCDC6 protein has been ascribed to CCDC6 rearrangements and to somatic 
mutations in several neoplasia. Recently, low levels of CCDC6 protein, in NSCLC, have 
been correlated with tumor prognosis. However, the mechanisms responsible for the 
variable levels of CCDC6 in primary tumors have not been described yet. 
We show that CCDC6 turnover is regulated in a cell cycle dependent manner. 
CCDC6 undergoes a cyclic variation in the phosphorylated status and in protein levels 
that peak at G2 and decrease in mitosis. The reduced stability of CCDC6 in the M phase 
is dependent on mitotic kinases and on degron motifs that are present in CCDC6 and 
direct the recruitment of CCDC6 to the FBXW7 E3 Ubl. The de-ubiquitinase enzyme 
USP7 appears responsible of the fine tuning of the CCDC6 stability, affecting cells 
behaviour and drug response.
Thus, we propose that the amount of CCDC6 protein in primary tumors, as 
reported in lung, may depend on the impairment of the CCDC6 turnover due to altered 
protein-protein interaction and post-translational modifications and may be critical 
in optimizing personalized therapy.
INtrODUctION
To cope  with the genotoxic damage, cells activate 
powerful DNA damage induced cell cycle checkpoints that 
coordinate cell cycle arrest with recruitment and activation 
of the DNA repair machinery [1-5]. The global relevance 
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of the cell cycle checkpoint pathways in maintaining 
genomic integrity is highlighted by the observation that 
loss, inactivation, or epigenetic silencing of checkpoint 
genes is frequently observed in cancer. Deletion of 
checkpoint genes has been shown to cause genomic 
instability and predisposition to transformation [6, 3]. 
Indeed, loss of DNA damage checkpoints, during early 
stages of tumorigenesis, may facilitate the acquisition 
of additional mutations over the time, determining 
aggressiveness and drug response in tumors. 
In previous work we documented that CCDC6 acts 
as a pro-apoptotic protein substrate of ATM, to sustain 
DNA damage checkpoints in response to genotoxic events 
[7, 8]. Moreover, CCDC6 protects genome integrity 
by modulating the activity of the phosphatase PP4C 
directed towards the de-phosphorylation on S139 of the 
histone H2AX (γH2AX) in response to DNA damage 
[9]. Consistent with these observations, we reported that 
CCDC6 deficiency affects the γH2AX foci formation 
and the repair of the DNA DSBs [9]. Thus, CCDC6 is an 
attractive candidate biomarker whose loss or inactivation 
could enhance tumor progression by impairing apoptosis 
thereby favoring cell survival and allowing the cells to 
overcome the barrier of a DNA damage response. The 
CCDC6 gene was originally identified because of its 
rearrangement with the RET tyrosine kinase in thyroid 
tumors [10], and with genes other than RET in non-solid 
tumors [11]. In most cancers that harbor the CCDC6 
gene rearrangements, the product of the normal allele of 
CCDC6 is either wholly absent or functionally impaired 
by a dominant negative mechanism [7]. Moreover, 
CCDC6 sporadic mutations have been reported in ovary 
and large intestine tumors (www.sanger.ac.uk/genetics/
CGP/cosmic). Recently, CCDC6-RET fusions and CCDC6 
point mutations [N394Y, T462A, S351Y, E227K] have 
been reported in NSCLC [12, 13]. Defective expression of 
CCDC6 has been observed in about 30% of NSCLC and 
negatively correlated to DFS and OS [14]. Importantly, in 
NSCLC cells, the defective expression of CCDC6 causes 
an impaired DNA repair by homologous recombination 
(HR), making these cells sensitive to PARP inhibitors. The 
concurrent treatment of cisplatinum and PARP inhibitors 
has shown a synergistic effect in CCDC6 deficient NSCLC 
cells [14]. 
CCDC6 has been recently recognized as a novel 
target of the E3 ubiquitin ligase FBXW7 for ubiquitin-
mediated proteasomal degradation [15]. 
The ubiquitin-mediated protein degradation pathway 
plays an important role in controlling the abundance 
of intracellular proteins and plays an essential role in 
maintaining normal cellular function, including the cell 
cycle. Deregulation of ubiquitin-mediated proteolysis 
results in the development of a variety of human cancers 
[16].
The removal of ubiquitin conjugates from target 
protein by de-ubiquitylating enzymes (DUBs) has 
emerged as an important regulatory mechanism in a 
range of cellular processes [17]. DUBs activity may be 
considered as important as the E3-ubiquitin ligases in 
cancer development, underscoring the dynamic and 
reversible nature of protein ubiquitylation. Several DUBs 
have been found to function in the DNA damage response, 
including ubiquitin-specific protease 1 (USP1), USP7 
and USP28 [18, 19]. USP7 (also known as HAUSP) is 
a DUB for several tumor suppressors [20]. Lately, USP7 
has been predicted as a major DUB for CCDC6 [21]. 
Here, we investigated if USP7 is specifically able to 
interact with CCDC6, controlling the CCDC6 stability 
and counteracting the FBXW7-mediated ubiquitylation of 
the protein. 
In this work we have analysed the post-translational 
modifications and the mechanisms regulating CCDC6 
protein turnover during cell cycle progression in order to 
establish whether the increased degradation or the reduced 
stability of CCDC6 might drive a different sensitivity to 
PARP inhibitors in cancer cells.
rEsULts
ccDc6 levels are regulated in a cell cycle 
dependent manner by phosphorylation events 
To investigate the regulation of CCDC6 protein 
levels during the cell cycle, human HeLa cells were 
synchronised at the G1/S boundary using a double 
thymidine (TT) block, then released into the cell cycle. 
The time course experiment showed several post-
translational modifications of CCDC6 protein at different 
time points (Figure 1A). In order to better discern the 
CCDC6 behaviour during the cell cycle, we utilized 
different chemical treatments to block the cells in specific 
phases. We observed a cyclic variation of CCDC6 levels 
that increased at boundary G1/S, picked at G2, and 
appeared upshifted in mitotic phase (Figure 1B). In order 
to focus on the CCDC6 modifications in mitosis, HeLa 
cells were then treated with nocodazole for 16 h, collected 
by shake-off, plated again and analyzed at different time 
points for a mitotic time course. The product of CCDC6 
appeared as multiple bands on SDS-page gels at time 0, 
from the nocodazole release. The shifts were maintained 
up to 2 hours, while they disappeared at 4, 8 and 10 hours 
when the protein seemed to be stabilized (Figure 1C). 
Calf intestinal phosphatase (CIP) treatment determined a 
significant decrease of the shifted bands at time 0, thus 
suggesting that the modifications observed in mitosis 
might depend on phosphorylation events (Figure 1D). 
The specific inhibition of cyclin–dependent kinase 1 
(CDK1) by RO3306 reverted most of the shifts observed 
by electrophoresis. In addition, the pretreatment with the 
specific inhibitor of glycogen synthase kinase 3 (GSK3), 
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SB216763, also reverted the modifications detected for 
CCDC6 in mitosis (Figure 1E).
We maintained the CCDC6 mitotic phosphorylation 
status by keeping the cells in nocodazole for additional 2, 4 
and 6 hours, after a pretreatment of 16 hours. The addition 
of the CDK1 inhibitor RO3306, during the nocodazole 
maintenance, impeded the CCDC6 post-translational 
modifications that occurred in mitosis, suggesting that 
CCDC6 is kept in the phosphorylated status mainly by 
CDK1 (Figure 2A). At 2 and 4 hours from nocodazole 
release the non-phosphorylated status of CCDC6 was 
mildly reverted by the okadaic acid addition suggesting 
that the activity of the mitotic kinases keeps the CCDC6 
phosphorylation status in mitosis as well as phosphatases 
contribute to regulate the CCDC6 phosphorylation status 
at mitotic exit (Figure 2B). In mitotic cells, treated with 
the proteasome inhibitor, MG132 (up to 4 hours), CCDC6 
shows a reduced mobility on SDS-PAGE suggesting that 
in these conditions CCDC6 is stuck in a phosphorylated 
status (Figure 2C). The MG132 treatment causes a reduced 
degradation of cyclin B1 that maintain CDK1 active on 
newly synthetized CCDC6 [22]. 
ccDc6 gene product binds cDK1 and GsK3 
mitotic kinases 
We wanted to investigate if CCDC6 was able to 
interact with the mitotic kinases, whose inhibitors reverted 
the CCDC6 phosphorylation observed in mitosis. To 
this aim we performed a S-protein pull-down in mitotic 
HeLa Kyoto cells, stably expressing S-tag-GFP-CCDC6 
construct [23]. By this experiment we identified a specific 
interaction between CCDC6 and endogenous cyclin B1, a 
component of the CDK1-cyclinB complex. Moreover, the 
mitotic pull down showed that CCDC6 was also able to 
interact with the GSK3 kinase (Figure 2D). Interestingly, 
Figure 1: ccDc6 protein levels are regulated through the cell cycle. A) CCDC6 levels increase from G1 to mitosis. Human 
HeLa cells were synchronized at the G1/S boundary by double thymidine block (TT block), then released into the cell cycle. Samples 
were analysed by SDS-PAGE and immunoblotted using the specific antibodies at the times shown after release from the block. b) HeLa 
cells were synchronized at the G1/S boundary by TT block, at the G2 phase by the CDK1 inhibitor RO3306, in mitosis after treatment 
with 100 ng/ml nocodazole (Noco) for 16 hours. Floating cells were separated from adherent and samples were analysed by immunoblot 
using the anti-CCDC6 antibody. c) Human HeLa cells were treated with 100 ng/ml nocodazole for 16 hours. Floating, mitotic cells, were 
separated from adherent (interphase) cells, plated again and samples were taken at the indicated times and analysed by immunoblotting 
using the indicated antibodies. D) HeLa cells were synchronized as in C and collected at time 0. Extracts were treated in vitro with CIP, as 
indicated. Therefore, samples were taken and analysed by immunoblotting with the indicated antibodies. Anti-MPM2 is utilized as indicator 
of mitotic arrest. E) HeLa cells were synchronized as in C, and cells were treated with RO3306 (9 μM for 2 hours) or with SB216763 (10 
μM for 4 hours) before the nocodazole release, as indicated. Samples were analysed by SDS-PAGE and immunoblotted using the indicated 
antibodies.
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the endogenous CCDC6, that is likely to be pulled down 
by the heterodimerization with the S-tag-CCDC6 protein, 
appeared to be shifted as well on the gel in the mitotic 
lysate. Moreover, the hybridization with the phospho-
antibody anti-MPM2, originally cloned on the basis of 
its ability to recognize mitotic phosphorylated residues 
on Cdk1/2 consensus motifs [22; 24-26], clearly showed 
immunoreactivity for CCDC6 in a pull down performed 
on mitotic extracts (Figure 2D). CCDC6 truncated mutants 
[(1-101) and (1-223)] did not show CCDC6 protein shifts 
after nocodazole release, suggesting that the target residues 
of the mitotic kinases may be located downstream of the 
aminoacid 223 in the CCDC6 sequence (Supplementary 
Figure 1). Several Serine/Threonine consensus for 
both CDK1 and GSK3 mitotic kinases (http://scansite.
mit.edu) have been predicted in the CCDC6 protein 
sequence. We performed a CCDC6 pull-down in mitotic 
extracts from HeLa Kyoto S-tag-GFP-CCDC6 cells 
overexpressing CDK1 or GSK3. In pull-down of cells 
overexpressing CDK1 we detected a predominant 
immunoreactivity for phosphoserine residues of CCDC6, 
while in pull-down from cells overexpressing GSK3 
kinase we observed a predominant immunoreactivity of 
the phosphothreonine residues of CCDC6. By treating the 
cells with RO3306 or SB216763 we were able to impede 
prevalently the recognition of CCDC6 phosphorylated 
residues, respectively, by antiphosphoserine and the 
antiphosphothreonine antibodies. These data support 
the idea that in mitosis the phosphoserine residues of 
CCDC6 are predominantly substrates of CDK1, while the 
phosphothreonine residues are predominantly substrates of 
GSK3 (Figure 2E and 2F).
Figure 2: ccDc6 behaviour during mitotic arrest depends on the cDK1 activity. A) HeLa cells were treated as in (1C). 
RO3306 and nocodazole treatment were maintained for additional 6 hours, before sampling and analysis by immunoblot, as indicated. b) 
HeLa cells were synchronized as in 1C, in presence or absence of Okadaic Acid (25 nM, one hour before arrest in mitosis) collected at the 
indicated times and analysed by immunoblotting using the indicated antibodies. c) Cells were treated with MG132 (10 μM) for 2 hours 
before arrest in mitosis as in (1C) and maintained in MG132 for additional 4 hours. Samples were immunoblotted with the antibodies shown. 
D) S-tag Pull Down of HeLa-Kyoto S-tag-GFP-CCDC6 asynchronous or mitotic extracts were analysed by SDS-PAGE and immunoblotted 
with the anti-cyclin B and anti-GSK3 antibodies, as shown. The anti-CCDC6 hybridization detected the S-tag-CCDC6 and the endogenous 
CCDC6, as indicated. The proteins expression in the surnatant is shown on the left side of the immunoblot. E) F) S-tag Pull Down of HeLa-
Kyoto S-tag-GFP-CCDC6 asynchronous or mitotic extracts from cells overexpressing CDK1 (E) or GSK3 (F) constructs previously treated 
with RO3306 at 9 μM for 2 hours or with SB216763 at 10 μM for 4 hours, respectively, before arrest in mitosis, as indicated, were analysed 
by SDS-PAGE and immunoblotted with the specific antibodies, as shown. The immunoblots of the whole cell lysates (WCL) are shown at 
the bottom of the panels E and F, respectively. 
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Mutations of the phosphoresidues in the ccDc6 
degron motifs for FbXW7 recognition sites affect 
ccDc6 cell cycle regulated turnover
Proper phosphorylation of protein substrates 
is required for FBXW7 recognition and targeting for 
degradation [27]. Recently, CCDC6 has been recognised as 
a novel FBXW7 E3 ubiquitin ligase (Ubl) substrate [15]. 
In order to determine if CCDC6 was modified by HA-
Ubiquitin, we performed an immunoprecipitation assay 
with myc-CCDC6 construct and we detected CCDC6 
modifications, reminiscent of ubiquitinylation (Figure 
3A). We next determined that recombinant CCDC6 is 
directly ubiquitylated by the reconstituted FBXW7-
containing Skip1-Cullin-Fbox (SCF) complex, by an in 
vitro assay (Figure 3B). Interestingly, the incubation with 
CDK1 enhanced the FBXW7-mediated ubiquitination of 
the recombinant GST-CCDC6, in support of the primary 
role exerted by this kinase (Supplementary figure 2). 
Furthermore, we observed that transient silencing of 
FBXW7 in HeLa cells was able to stabilize the CCDC6 
protein in a dose dependent manner, in vivo (Figure 3C). 
In CCDC6 protein sequence, the residues serine 
359, serine 413 and threonine 427 have been recognized 
as canonical FBXW7 degron motifs and conserved 
across different species [15]. A CCDC6 mutant in the 
mentioned residues showed an increased half life when 
overexpressed in HeLa cells in presence of cycloheximide 
(CHX), an inhibitor of de novo protein synthesis (Figure 
3D). Moreover, in experiment of co-immunoprecipitation 
we have observed that the CCDC6 triple mutant is 
impaired in its binding to FBXW7 (Figure 3E). Thus, the 
data produced by us and by others [15] suggest that the 
Figure 3: FbXW7 increases ccDc6 turnover via increasing ccDc6 ubiquitination. A) 293T cells were transfected with 
the indicated plasmids. The amount of ubiquitinated CCDC6 was analysed by immunoprecipitation (IP) of myc-CCDC6 followed by 
immunoblotting (IB) with anti-HA. b) Affinity-purified GST-CCDC6 recombinant protein (Abnova H00008030-P01) was incubated with 
purified E1, E2, His-ubiquitin and 293T cell lysate as source of E3 ligase FBXW7, from cells transiently transfected with HA-FBXW7, at 
37°C for 60 min (according to manufacturer instructions; see M&M). The ubiquitination reaction products were resolved by SDS-PAGE 
and probed with anti-Histidine antibody and anti-CCDC6 antibody. c) Sh-FBXW7 constructs, at 2, 3 or 4 μg doses, were transiently 
transfected in 293T cells. Cell lysates were immunoblotted with the indicated antibodies. Expression levels of cyclin E are shown as a 
representative substrate of FBXW7. D) CCDC6 turnover rate is reduced in HeLa cells overexpressing the mutated triple mutant CCDC6 
construct (SST359/413/427AAA) (TM), compared to the CCDC6 wild type, (WT), construct overexpressing cells. Cells were treated 
with cycloheximide (CHX) (100 ng/ml) for the indicated times. Cell lysates were immunoblotted with the indicated antibodies. E) Myc-
CCDC6 WT and TM constructs were cotransfected with HA-FBXW7 into 293T cells in presence of MG132 (25 μM). Cell lysates were 
immunoprecipitated with anti-myc and immunoblotted with the anti-HA antibody. Whole cell lysates, shown at the bottom of the figure, 
have been immunoblotted with the indicated antibodies.
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phosphorylation of the CCDC6 residues, that are targets 
of GSK3, allows FBXW7 to act as a negative regulator 
of CCDC6 stability. In order to define if the degradation 
of CCDC6 in mitosis is dependent on FBXW7 binding 
upon phosphorylation of the GSK3 target residues 
(S359, S413, T427), we expressed in HeLa cells the 
single, S359A, double, ST359/427AA (DM), and triple, 
SST359/413/427AAA (TM) mutants of CCDC6 that 
showed a defect in the mitotic shifts after 16 hours of 
treatment with nocodazole (time 0 from nocodazole 
release) with a progressive reduction that appeared related 
to the number of the modified residues, with a striking 
protein stabilization observed in the triple mutant (Figure 
4A). Moreover, the overexpression of myc-CCDC6 
constructs, mutated in all the phosphodegron recognition 
sites (triple mutant, TM), did not show the cyclic variation 
observed for the myc-CCDC6 wt protein during the 
mitotic time course (Figure 4B). Therefore, mutations in 
the CCDC6 phosphoresidues, recognized by GSK3, are 
responsible of the impaired turnover of CCDC6 during the 
progression of the cell cycle.
FbXW7 targets ccDc6 for proteasomal 
degradation during mitotic arrest
To further study the role of E3-Ubl FBXW7 in the 
regulation of endogenous CCDC6 protein during the 
cell cycle we employed the HCT116 FBXW7-/- colon 
cancer cells [28]. First, we observed that the regulation 
of CCDC6 stability was found to be proteasome-
dependent in HCT116 wt cells, as MG132 treatment 
leads to stabilization of endogenous CCDC6 (Figure 5A). 
Moreover, we report that the HCT116 FBXW7-/- have 
increased levels of endogenous CCDC6 at western blot 
when compared with HCT116 wild type cells (Figure 
5B). The impairment of the FBXW7 activity in HCT116 
FBXW7-/- is confirmed by the cyclin E stabilization at 
western blot, that is not detected in wild type HCT116 
cells [29]. Nevertheless, the CCDC6 mRNA levels 
were substantially constant in these cells (Figure 5C). 
In experiments performed with the cycloheximide 
we observed a delayed CCDC6 turnover (nearly 60 
minutes) in the HCT116 FBXW7-/- cells compared to 
the HCT116 wt cells (Figure 5D). To further analyse the 
role of FBXW7 in the regulation of the CCDC6 turnover 
in mitosis, the HCT116 cells (wt and FBXW7-/-) were 
synchronized and the protein extracts collected throughout 
the mitotic time course. During mitotic arrest, CCDC6 
degradation was attenuated in HCT116 FBXW7-/- cells, 
compared to the wild type cells (Figure 5E), indicating 
that the fluctuations of endogenous levels of CCDC6 
protein are mostly dependent on the FBXW7 activity in 
mitosis. Interestingly, in HCT116 FBXW7-/- the stabilized 
CCDC6 protein appeared mainly localized in the cytosol 
(Figure 5F), a condition that has been related to tumor 
growth [30, 31]. 
Figure 4: ccDc6 turnover is impaired by mutations in the phosphoresidues of the ccDc6 degron motifs recognized 
by FbXW7. A) Assessment of the stability of the CCDC6 mutant proteins [single (S359A), double (ST359/427AA) and triple 
(SST359/413/427AAA) mutants] by western blotting at mitotic arrest, after 16 hours nocodazole (100ng/ml) and hybridization with 
the indicated antibodies. b) Assessment of CCDC6 TM levels by western blot during mitosis. The mitotic time course indicates when 
synchronized cells were collected on relation to the onset of mitotic arrest, that is, -3 denotes 3 hours before mitosis (M) and +3 denotes 
3 hours after cells entered mitosis and beyond (+6, +9). Anti-MPM2 is utilized as indicator of mitotic arrest. Anti-tubulin is indicator of 
equal loading.
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the de-ubiquitinase UsP7 stabilizes ccDc6 
protein 
USP7 is the de-ubiquitinase (DUB) predicted to 
remove ubiquitin from CCDC6 [21]. We verified that 
endogenous CCDC6 interacts specifically with USP7 
(Figure 6A). The myc-tagged CCDC6 truncated mutant 
(1-223) still coimmunoprecipitated with USP7, suggesting 
that the aminoterminus of CCDC6 is sufficient for the 
CCDC6 binding to USP7 (Figure 6B). Recent findings 
unveiled that in NSCLC cell lines, H1975, H1299, A549 
and H460, CCDC6 transcripts did not show significant 
variability, while quite different CCDC6 protein levels 
were observed [14]. Moreover, by cycloheximide 
experiments differences of the CCDC6 half life were 
detected in the NSCLC cells (Supplementary Figure 3). 
Thus, in the lung cellular system, the H1975 and the 
H1299 cells, characterized by high levels of USP7 protein, 
show more CCDC6 product compared to the H460 and the 
A549 NSCLC cells that expresse less USP7 and are almost 
deficient for CCDC6 protein (Figure 6C). By modulating 
the USP7 intracellular amount, we were able to alter 
Figure 5: FBXW7 deficiency leads to CCDC6 stabilization and affects CCDC6 turnover rate. A) HCT116 wild type cells 
were treated with MG132 (20 μM) for 6 hours before harvesting. Equal amounts of cell lysates were immunoblotted with anti-CCDC6 
or anti-tubulin antibodies. b) Indicated wild type, FBXW7-/- and USP7-/- cells were harvested and equal amounts of cell lysates were 
immunoblotted with anti-CCDC6, cyclin E, USP7 or tubulin antibodies. c) CCDC6 relative mRNA expression by quantitative RT-PCR 
in human HCT116 WT, FBXW7-/- and USP7-/- cells. D) CCDC6 turnover rate is delayed in FBXW7 deficient cells and accelerated in 
USP7 deficient cells. Indicated wild type (WT), FBXW7-/- and USP7-/- HCT116 cells were treated with cycloheximide (CHX) (100 ng/
ml) for the indicated times. Cell lysates were immunoblotted with the indicated antibodies. E) Assessment of CCDC6 levels by western 
blot during mitotic time course as in (4B) in HCT116 WT, FBXW7-/- and USP7-/-. Anti-MPM2, Cyclin A, Cyclin B and Plk1 have been 
utilized as indicators of mitotic arrest. F) Localization of CCDC6 by immunofluorescence assay in HCT116 WT and FBXW7-/- cells. After 
fixation, cells were permeabilized and stained with anti-CCDC6 antibody. Serial confocal sections were collected. Bars, 11 μm. The 3D 
reconstruction is shown (lower panels). Results from two different experiments were plotted as percent nuclei (grey) and cytosol  (white) 
localization (n > 100 cells). Error bars, SD; p < 2e_11. 
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Figure 6: ccDc6 interacts with UsP7. A) Endogenous CCDC6 and USP7 proteins obtained from parental 293T cells were 
coimmunoprecipitated. The immunocomplexes were analysed by western blotting using the indicated antibodies. b) CCDC6 wt or the 
CCDC6 (1-223) deleted mutant constructs, transfected in 293T cells, were immunoprecipitated with anti-myc. Then, the immunocomplexes 
were analysed by western blot using the indicated antibodies. c) Immunoblot analysis of USP7 and of CCDC6 in NSCLC-derived cell 
lines: ADC derived cell lines (NCI-H1975, NCI-H460 and A549) and Large Cell Carcinoma cell line (NCI-H1299). Antitubulin is shown as 
loading control. D) Immunoblot analysis of CCDC6 expression in HeLa cells and in H460 cells overexpressing (+) FLAG-HA-USP7. Anti-
FLAG immunoblot shows the USP7 transfection efficiency. Antitubulin is shown as loading control. E) 293T cells were transfected with 
myc-CCDC6 WT and TM constructs. Whole cell lysates (WCL) were prepared and equal amounts of proteins were immunoprecipitated 
with anti-myc. Then, the immunocomplexes were analysed by western blot using the indicated antibodies. F) Immunohistochemical 
analyses of human lung tumor tissues. Formalin fixed paraffin embedded lung tissue sections were stained with antibody against CCDC6 
(a,b) or USP7 (c,d). Representative examples are shown of: CCDC6 low expression pattern (a), CCDC6 high expression pattern (b), USP7 
low expression pattern (c), USP7 high expression pattern (d). Magnification: a, b, c, d x 200. G) Drug sensitivity to cisplatinum and olaparib 
in HCT116wt, FBXW7-/-, CCDC6-/-, USP7-/-, CCDC6-/-CCDC6+, and USP7-/-CCDC6+ was determined by a modified 3-(4,5-dimethylthiazole-
2-yl)-2-5-diphenyltetrazolium bromide assay, [CellTiter 96 AQueous One Solution assay (Promega)], as 50% inhibitory concentration 
(IC50) values. H) Combination index according to 1:2 concentration ratios of cisplatin and olaparib in HCT116 wt, FBXW7-/-, CCDC6-/- , 
USP7-/- , CCDC6-/- CCDC6+, USP7-/- CCDC6+ cells are shown. CI < 1, CI = 1 and CI > 1 indicate synergism, additive effect and antagonism, 
respectively.
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the levels of CCDC6 protein in different cell types. The 
overexpression of FLAG-HA-USP7 in HeLa and in H460 
cells increased the amount of CCDC6 protein (Figure 6D). 
The knockdown of USP7 in HCT116 cells [32] decreased 
CCDC6 protein (Figure 5B), without affecting the CCDC6 
mRNA, as shown in the Figure 5C. The knockdown of 
USP7 in HCT116 altered the CCDC6 half life, affecting 
its stability (Figure 5D). In order to determine the effects 
of the de-ubiquitinase USP7 on the CCDC6 turnover, we 
evaluated the amount of CCDC6 at different time point in 
a mitotic time course performed in HCT116 cells that were 
deficient for USP7. In these cells, the impairment of the 
CCDC6 stability is mostly evident at 6 and 9 hours from 
nocodazole release (Figure 5E). In general, we observed 
reduction of CCDC6 protein after USP7 knockdown, 
consistently with the fact that ubiquitin is not removed 
any longer from CCDC6. In an in vitro ubiquitination 
assay we observed that the ubiquitination mediated by 
FBXW7 complex on the recombinant CCDC6, as shown 
in the figure 3B, is impaired by the presence of USP7 
(Supplementary Figure 4). We also observed that alanine 
substitutions of the mentioned S/T residues enhanced the 
interaction of CCDC6 with USP7 (Figure 6E). Thus, we 
hypothesized that CCDC6 phosphorylation at the residues 
that are targets of CDK1 and GSK3 may limit the CCDC6-
USP7 interaction. Interestingly, the immunostaining of 62 
primary NSCLC showed that expression levels of USP7 
directly correlated to CCDC6 protein levels (Figure 6F). 
The correlation of CCDC6 and USP7 positivity staining 
intensity was proved to be statistical significant (χ2 test: p 
≤ 0,05) in the analyzed samples.
Recently, we have reported that the H460 NSCL 
cancer cells, that show low levels of CCDC6 protein, 
are sensitive to the PARP inhibitor olaparib, whereas 
H1975 cells, harboring high levels of CCDC6 protein, are 
resistant to olaparib and become sensitive when CCDC6 
is knocked down [14]. Here we show that the knockdown 
of USP7 reduces the levels of CCDC6 in HCT116 cells 
(Figure 5B) and increases their sensitivity to olaparib 
(Figure 6G and 6H). Moreover, the combination of 
cisplatinum and olaparib has a synergistic effect on these 
cells. In HCT116 USP7-/- and in HCT116 CCDC6-/-, 
that we have generated (Supplementary Figure 5A), the 
reconstitution of CCDC6 is sufficient to revert the olaparib 
sensitivity, suggesting that CCDC6 levels are the critical 
determinant for the olaparib sensitivity (Figure 6G and 
6H; Supplementary Figure 5B). Therefore, we suggest 
that the clinical usage of USP7 inhibitors [33, 34], by 
downregulating the CCDC6 levels, might increase the 
sensitization to olaparib and enhance the response to 
standard chemotherapeutics in combined therapy in cancer 
cells.
DIscUssION
In this study we report for the first time that CCDC6 
is a cell cycle regulated protein in mammalian cells. 
CCDC6 levels increase at boundary G1/S, pick at G2 
and decrease in mitosis; the same evidences observed in 
Xenopus laevis extracts support the notion that CCDC6 
behaviour is highly conserved (Supplementary Figure 
6). The CCDC6 modifications detected in cell cycle are 
mostly dependent on phosphorylation events generated by 
multiple cell cycle dependent kinases that prime CCDC6 
for degradation in mitosis in a proteasome dependent 
manner. 
As the control of CCDC6 stability involves 
both ubiquitylation and deubiquitylation processes we 
have characterized FBXW7 as the E3 Ubiquitin ligase 
responsible for the CCDC6 degradation and USP7 as the 
de-ubiquitynating enzyme that counteracts the FBXW7 
activity for CCDC6 stabilization. The stability of CCDC6 
in G2, also observed in previous work, has pointed out 
to the role of CCDC6 in the G2/M checkpoint [9]. Here, 
we report a critical role of FBXW7 in the control of 
CCDC6 homeostasis in mitosis by regulating its ubiquitin-
proteasomal degradation and providing evidences that the 
CCDC6 post-translational regulation in the cell cycle may 
account for differences in cancer cells drug response. 
Recent findings unveiled that CCDC6 different 
levels in NSCLC are probably due to variations in protein 
stability and/or turnover, since CCDC6 transcript did 
not show significant variability in NSCLC cell lines and 
NSCL FFPE primary samples [14]. 
Thus, we hypothesized that the alteration of CCDC6 
steady-state, controlled by FBXW7 or USP7, may help to 
select tumors that carry FBXW7 loss/mutation or USP7 
mutations, as potentially responsive to olaparib treatment. 
Our study shows that the FBXW7 and USP7 enzymes 
keep CCDC6 protein in check of G2/M phase during the 
cell cycle. In tumors overexpressing USP7, or carrying 
an impaired FBXW7-mediated degradation, CCDC6 
is highly stabilized. Conversely, tumors harbouring 
barely detectable levels of USP7 have reduced amount 
of CCDC6 protein. We recently reported that defective 
CCDC6 drives a PARP inhibitors sensitivity in NSCLC. 
Thus, the identification of NSCL tumors that are deficient 
in USP7 may provide insight into the selection of patients 
that could benefit of the PARP inhibitors in combination 
to the conventional chemotherapy. Thus, we wonder if the 
use of USP7 inhibitors, by reducing CCDC6 stability, may 
increase the PARP inhibitors sensitivity and improve the 
management of NSCLC patients. 
FBXW7 is considered an haploinsufficient tumor 
suppressor that targets several proto-oncoproteins for 
degradation, including cyclin E, Myc, c-jun, Mcl1 
[27, 35-43]. Here, we enroll CCDC6, a protein of the 
DNA Damage response, as a novel FBXW7 substrate, 
suggesting that patients carrying FBXW7 mutations might 
present a more stable CCDC6 protein being more resistant 
to olaparib combination for their treatment. However, our 
data show that cells null for FBXW7 mainly maintain a 
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cytosolic localization of CCDC6. As we have previously 
reported, SUMO2 post-translational modifications of 
CCDC6, occurring when ubiquitynation is impaired, 
mainly localize CCDC6 in the cytosol limiting the CCDC6 
nuclear activity [30-31]. In our system we have identified 
a correlation between the genetic status of FBXW7 and 
the sensitivity to cisplatinum, as the FBXW7 null cells, 
in which CCDC6 is more stable, are highly responsive 
to platinum salts. Furthermore, our observations suggest 
that CDK1 possibly primes CCDC6 in order to favour 
GSK3 phosphorylation in the degron motifs and promotes 
its binding to FBXW7 in a cellular context. As well the 
phosphorylation events might also affect the USP7 binding 
in mitosis, since the CCDC6-USP7 interaction appears to 
be stronger during the cellular interphase, when CCDC6 
is more stable (Supplementary Figure 7). Our model 
suggest that USP7 might act by removing the ubiquitin 
from CCDC6 protein in cells exposed to DNA damage 
in order to protect CCDC6 from FBXW7-mediated 
degradation. In our study we show that about 20% of 
NSCLC exhibit reduced USP7 expression and also have 
barely detectable levels of CCDC6. The loss of CCDC6 
can cause the impairment of HR DNA repair providing the 
indications for the PARP inhibitors treatment in NSCLC or 
in tumors that harbour low levels of CCDC6 or of USP7. 
We wonder if the use of specific USP7 inhibitors would 
enhance CCDC6 turnover in order to sensitize cancer 
cells to the PARP inhibitors in combination with standard 
chemotherapies. Moreover, it has been reported that 
USP7 reduction is related to chemo- and radio- therapy 
resistance in lung adenocarcinomas [44]. Therefore, 
the identification of CCDC6 as a novel USP7 substrate 
provides the rationale for novel personalized therapy in 
NSCLC patients carrying USP7 deficiency. 
MAtErIALs AND MEtHODs
cell lines, drugs and chemicals
HCT116 wild type, FBXW7-/- and USP7-/-, 
generated by Dr Bert Vogelstein and obtained by the 
GRCF Cell Center and BioRepository, Baltimore, MD, 
were grown in McCoy’s 5A media (Gibco, Paisley, UK) 
supplemented with 10% fetal bovine serum, 1% penicillin/
streptomycin, 2mM L-glutamine (Gibco, Paisley, UK) 
[28; 32]. The human cell lines H1975, H1299, H460, 
A549 were cultured in RPMI 1640 (Gibco, Paisley, UK), 
supplemented with 10% fetal bovine serum (Gibco, 
Paisley, UK), 1% penicillin/streptomycin (Gibco, Paisley, 
UK). No RET/PTC1 fusion or CCDC6 mutations have 
been reported in these cell lines [45]. HeLa Kyoto S-tag-
GFP-CCDC6 cells were generated by Ina Poser in the 
laboratory of Anthony Hyman [23], and were grown 
in DMEM (high glucose), 10% FCS, 1% penicillin/
streptomycin (Gibco, Paisley, UK).
Nocodazole, thymidine, SB-216763 and 
Cycloheximide were obtained from SIGMA-Aldrich, Inc. 
Deoxycytidine hydrochloride was from Fluka. MG132 
and RO3306 were obtained from Calbiochem (Darmstadt, 
Germany). Olaparib was provided by SelleckChem 
(AZD2281) and cisplatinum was from SIGMA-Aldrich, 
Inc. Okadaic acid was from Biomol International 
(Farmingdale, New York).
sensitivity test and design for drug combination
Antiproliferative activity was determined 
by a modified 3-(4,5-dimethylthiazole-2-yl)-2-5-
diphenyltetrazolium bromide assay, CellTiter 96 AQueous 
One Solution assay (Promega), as 50% inhibitory 
concentration (IC50) values. Briefly, cells were plated in 
quintuplicate in 96-well plates at a density of 1.000-3.000 
cells per well, and continuously exposed to each drug for 
144h. Each assay was performed in quintuplicate and IC50 
values were expressed as mean +/- standard deviation. The 
results of the combined treatment were analyzed according 
to the method of Chou and Talaly by using the CalcuSyn 
software program [46]. The resulting combination index 
(CI) is a quantitative measure of the degree of interaction 
between different drugs. A CI value of unity denotes 
additive activity while CI > 1 denotes antagonism, and CI 
< 1 denotes synergy between agents.
Plasmids and transfection
CCDC6 shRNA (pLKO.1 puro) was from Sigma-
Aldrich. For production of stable lines, HCT116 cells were 
transfected with a plasmid pool (shCCDC6, NM_005436) 
or a pool of nontargeting vectors (sh control) by the 
Nucleofection. PcDNA4ToA-CCDC6 plasmids were 
transfected with FuGene HD (Promega) and have been 
described elsewhere [7]. From myc- (pcDNA4ToAmyc-
his-CCDC6) template several myc-CCDC6 mutants at 
serine or threonine putative phosphorylation sites were 
created using the Quick Change Site Directed Mutagenesis 
Kit (Agilent, CA). To obtain the double and the triple 
mutant we used sequentially the single and double mutants 
as template with the other primers. The oligo sequences 
are reported in the Supplementary Table 1. Sh-FBXW7 
was kindly provided by Hiroyuki Inuzuka and Wenye 
Wei. Ubiquitin, FBXW7, HA-FLAG-USP7 plasmids were 
obtained from Origene Technologies, Inc.
Protein extract and western blot analysis
Total cell extracts were prepared with Ripa Buffer 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton 
X-100, 0.5% Na Deoxycholate, 0.1% SDS) and a protease 
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inhibitor cocktail (Roche). Immunoblotting experiments 
were carried out according to standard procedures and 
visualized using the ECL chemiluminescence system 
(Amersham/Pharmacia Biotech). 
real time Pcr
PCR reactions were performed on RNA isolated 
from different cell lines using RNeasy Mini Kit (Qiagen) 
and reverse-transcribed using MuLV RT (Invitrogen). qRT-
PCR was performed with Syber Green (Agilent) using 
already reported CCDC6 primers [47]. To calculate the 
relative expression levels we used the 2−ΔΔCT method. 
Immunofluorescence staining
Asynchronous cells were fixed with 4% 
paraformaldehyde and treated with phosphate-buffered 
saline (PBS)/0.25% Triton X-100. After staining with 
primary antibody, cells were washed in PBS and incubated 
for 30 min at room temperature with secondary antibody. 
Nuclei were visualized by staining with DAPI. Images 
were collected using a laser scanning confocal microscope 
(LSM 510; Carl Zeiss MicroImaging, Inc.) equipped with 
a plan Apo 63× NA 1.4 oil immersion objective lens. As 
previously described [48], the quantification of mean 
fluorescence intensities in selected regions of interest were 
performed using LSM 510 software. All z planes were 
volume rendered by LSM 510 software. 
tumors
Archival tumor samples from 62 patients (males 
and females, smokers and nonsmokers) with NSCL 
cancer were retrieved from the files of the Pathology 
Sections of the “Ospedale Cardarelli” of Naples (N=37) 
and from the files of the Marshall University, Virginia, 
USA (N=25), with informed consent and standard IRB 
approvals. Clinico-pathologic data were recorded. The 
patient age ranged between 35 and 80 years, with a 
mean of 63.5 years. Patients underwent surgery between 
2005 and 2010. After surgical resection, tissues were 
fixed in 10% neutral buffered formalin and embedded in 
paraffin blocks. Sections (4 μm thick) were stained with 
H&E. Histologic grading and pathological staging were 
performed according to WHO guidelines [49]. 
tMA
Tissue Micro-Array (TMA) was built using the most 
representative areas from each single case, obtained from 
the Pathology Section of the “Ospedale Cardarelli” of 
Naples (N=37). Tissue cores with a diameter of 0.3 mm 
were punched from morphologically representative tissue 
areas of each ‘donor’ tissue block and brought into one 
recipient paraffin block (3×2.5 cm) using a semiautomated 
tissue arrayer (Galileo TMA, Milan, Italy). 
IHc analysis
For light microscopy, tissues (25 whole sections 
and TMA) were fixed by immersion in 10% formalin 
and embedded in paraffin by standard procedures; 4 
μm sections were stained with haematoxylin and eosin 
(H&E) or processed for immunohistochemistry with 
anti-CCDC6 antibody, HPA-019051 (Sigma-Aldrich, Co. 
LLC), and anti-USP7 antibody, HPA-015641 (Sigma-
Aldrich, Co. LLC). The immunohistochemical staining 
of USP7 and CCDC6 was evaluated semiquantitatively 
as the percentage of positive cells (with either nuclear 
or cytoplasmic localization). Cells were classified as low 
staining, [e.g. 0 (<5%) and + (5-25%)] and high staining 
[++ (26-50%) and +++ (>50%)].
reagents and antibodies
Anti Cyclin E (sc-247), anti Cyclin B (sc-594), anti 
Cyclin A (sc-751), anti Aurora A (sc-25425), anti Plk1 (sc-
5585) and anti-Gsk3α/β (sc7291) were form Santa Cruz 
Biotechnology (CA, USA); anti-CCDC6 (ab56353) was 
from Abcam; anti-USP7 (A300-033A) was from Bethyl; 
anti-MPM2 (05-368) was from Millipore; anti-phospho-
Serine (# 37430) was from Qiagen; anti-phospho-
Threonine (# 9386) was from Cell Signaling Technology; 
anti-poly-Histidine (H1029) was from SIGMA-Aldrich, 
Inc. Secondary antibodies were from Biorad, California.
Ubiquitination assay
The in vitro ubiquitylation assays were performed 
with Ubiquitinylation kit (Enzo Life Sciences). Affinity-
purified GST-CCDC6 recombinant protein (Abnova 
H00008030-P01) was incubated with His-ubiquitin, 
purified E1, E2, ATP and the 293T cell lysate as source 
of E3 ligase FBXW7 (upon HA-FBXW7 or empty 
vector plasmids transient transfections). The cells were 
treated with MG132 (25µM) for eight hours before lysis. 
According to manufacturer instructions the reaction was 
performed at 37°C for 60 min and it was stopped by 
adding of 2X SDS-PAGE sample buffer. The reaction 
products were resolved by SDS-PAGE and probed with 
indicated antibodies.
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